Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I, Panel WHO. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.

Article  Google Scholar 

Bae HM, Min HS, Lee SH, Kim DW, Chung DH, Lee JS, Kim YW, Heo DS. Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer. 2007;58(1):112–5.

Article  PubMed  Google Scholar 

Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ. The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. Med Oncol. 2009;26(3):287–91.

Article  CAS  PubMed  Google Scholar 

Tamura Y, Fujiwara Y, Yamamoto N, Nokihara H, Horinouchi H, Kanda S, Goto Y, Kubo E, Kitahara S, Tsuruoka K, Tsuta K, Ohe Y. Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Res Notes. 2015;8:800.

Article  PubMed  PubMed Central  Google Scholar 

Oizumi S, Takamura K, Harada T, Tachihara M, Morikawa N, Honda R, Watanabe S, Asao T, Kunisaki M, Fukuhara T, Noro R, Kikuchi E, Tsutani Y, Tenma T, Kobayashi K, Dosaka-Akita H. North east Japan study group HLCCSG Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung HOT1201/NEJ024. Int J Clin Oncol. 2022;27(4):676–83.

Article  CAS  PubMed  Google Scholar 

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.

Article  CAS  PubMed  Google Scholar 

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, Oncology West Japan, G. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.

Article  CAS  PubMed  Google Scholar 

Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, Tamura T. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26(34):5589–95.

Article  CAS  PubMed  Google Scholar 

Saito M, Shiraishi K, Kunitoh H, Takenoshita S, Yokota J, Kohno T. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 2016;107(6):713–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaira K, Horie Y, Ayabe E, Murakami H, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol. 2010;5(4):460–5.

Article  PubMed  Google Scholar 

Chang YL, Wu CT, Shih JY, Lee YC. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Ann Surg Oncol. 2011;18(10):2952–60.

Article  PubMed  Google Scholar 

Jiang X, Liu Y, Chen C, Zhan Z, Yan Q, Guo Y, Wang Q, Li K. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases. Clin Lung Cancer. 2012;13(4):288–96.

Article  CAS  PubMed  Google Scholar 

Jia X, Chen G. EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features. Contemp Oncol. 2015;19(1):22–7.

Google Scholar 

Forest F, Yvorel V, Karpathiou G, Stachowicz ML, Vergnon JM, Fournel P, Tiffet O, Trombert B, Péoc’h M. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies. Hum Pathol. 2016;49:99–106.

Article  PubMed  Google Scholar 

Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B, Kim TM, Kim DW, Jeon YK, Chung DH. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: an analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. Lung Cancer. 2017;106:131–7.

Article  PubMed  Google Scholar 

Li X, Wang D, Zhao Q, Ren D, Ren F, Chen G, Liu H, Chen J. Clinical significance and next-generation sequencing of Chinese pulmonary sarcomatoid carcinoma. Sci Rep. 2017;7(1):3947.

Article  PubMed  PubMed Central  Google Scholar 

Saffroy R, Fallet V, Girard N, Mazieres J, Sibilot DM, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Oncotarget. 2017;8(26):42428–37.

Article  PubMed  PubMed Central  Google Scholar 

Chen X, Zhang Y, Lu J, Xu C, Liang J, Wang F, Sun W, Fang S, Yuan J, Wang H, Wang H, Liu X, Chen L. Pulmonary sarcomatoid carcinoma with ALK rearrangement: frequency, clinical-pathologic characteristics, and response to ALK inhibitor. Transl Oncol. 2017;10(2):115–20.

Article  PubMed  PubMed Central  Google Scholar 

Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ. Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling. J Thorac Oncol. 2017;12(6):932–42.

Article  PubMed  Google Scholar 

Sim JK, Chung SM, Choi JH, Oh JY, Lee SH, Kim JH, Min KH, Hur GY, Shim JJ, Kang KH, Shin BK, Lee JH, Lee SY. Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma. Korean J Intern Med. 2018;33(4):737–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer-a systematic review and meta-analysis. Lung Cancer. 2018;123:76–82.

Article  PubMed  Google Scholar 

Liu XW, Chen XR, Rong YM, Lyu N, Xu CW, Wang F, Sun WY, Fang SG, Yuan JP, Wang HJ, Wang WX, Huang WB, Xu JP, Yue ZY, Chen LK. MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: a multi-center study. Transl Oncol. 2020;13(12): 100868.

Article  PubMed  PubMed Central  Google Scholar 

Manabe S, Kasajima R, Murakami S, Miyagi Y, Yokose T, Kondo T, Saito H, Ito H, Kaneko T, Yamada K. Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique. Thorac Cancer. 2020;11(8):2262–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kojima K, Imai S, Samejima H, Fujiwara A, Tokunaga T, Yoon H, Okishio K. PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study. BMC Cancer. 2022;22(1):1066.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ushiki A, Koizumi T, Kobayashi N, Kanda S, Yasuo M, Yamamoto H, Kubo K, Aoyagi D, Nakayama J. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol. 2009;39(4):267–70.

Article  PubMed  Google Scholar 

Saitoh M, Niijima M, Takiguchi Y, Hiroshima K, Fujita Y, Nishio K, Tatsumi K. An early event of EGFR mutation in pleomorphic carcinoma of the lung. Int J Clin Oncol. 2011;16(6):770–3.

Article  PubMed  Google Scholar 

Zou F, Xie G, Ma JA, Zhou DA, Jiang YI, Zheng JY. Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: a case report. Oncol Lett. 2015;9(5):2239–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masuda K, Tokito T, Azuma K, Yanagida E, Nakamura M, Naito Y, Matsuo N, Ishii H, Yamada K, Akiba J, Hoshino T. Pulmonary pleomorphic carcinoma: a case harboring EGFR mutation treated with EGFR-TKIs. Thorac Cancer. 2018;9(6):754–7.

Article  PubMed  PubMed Central  Google Scholar 

Lin L, Huang F, Chen F, He Y, Hu J, Cao X. Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib. J Int Med Res. 2018;46(8):3491–7.